Company / R&D Expense
FILANA THERAPEUTICS, INC. R&D Expense History
FY2011-FY2015 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$4.9M
FY2015
5-year range
$4.9M / $21.1M
FY2011-FY2015
Trend
-35.3%
vs FY2014
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D Expense has declined for 4 consecutive years, from $21M in FY2011 to $5M in FY2015.
Based on SEC 10-K filings.
$5M in FY2015 with a 3-year CAGR of -32.2%.
Declined from $8M to $5M over the past 2 years.
R&D Expense over time
Growth rates
- 3-Year CAGR
- -32.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- FILANA THERAPEUTICS, INC.'s r&d expense has declined for 4 consecutive years.
- 3-year CAGR of -32.2%, indicating a declining trend.
- In FY2015, r&d expense decreased 35.3% year-over-year.
- Peak r&d expense was recorded in FY2011.
Company context
Key Data Points
- Altman Z-Score 3.76 (safe zone, above 2.9 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2015 | $4.9M | -35.3% |
| FY2014 | $7.6M | -8.4% |
| FY2013 | $8.3M | -47.3% |
| FY2012 | $15.7M | -25.2% |
| FY2011 | $21.1M | - |
As of FY2015 · SEC 10-K · Updated Jun 24, 2026